AngioDynamics (ANGO) Stock Forecast, Price Target & Predictions
ANGO Stock Forecast
AngioDynamics stock forecast is as follows: an average price target of $17.00 (represents a 122.51% upside from ANGO’s last price of $7.64) and a rating consensus of 'Buy', based on 3 wall street analysts offering a 1-year stock forecast.
ANGO Price Target
The average price target for AngioDynamics (ANGO) is $17.00 based on 1-year price targets from 3 Wall Street analysts in the past 3 months, with a price target range of $22.00 to $12.00. This represents a potential 122.51% upside from ANGO's last price of $7.64.
ANGO Analyst Ratings
According to 3 Wall Street analysts, AngioDynamics's rating consensus is 'Buy'. The analyst rating breakdown for ANGO stock is 0 'Strong Buy' (0.00%), 3 'Buy' (100.00%), 0 'Hold' (0.00%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).
AngioDynamics Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| Apr 05, 2024 | Steven Lichtman | Oppenheimer | $12.00 | $6.40 | 87.50% | 57.07% |
| Jan 06, 2023 | - | Raymond James | $22.00 | $15.48 | 42.12% | 187.96% |
| Jul 13, 2022 | - | Raymond James | $27.00 | $20.02 | 34.87% | 253.40% |
The latest AngioDynamics stock forecast, released on Apr 05, 2024 by Steven Lichtman from Oppenheimer, set a price target of $12.00, which represents a 87.50% increase from the stock price at the time of the forecast ($6.40), and a 57.07% increase from ANGO last price ($7.64).
AngioDynamics Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | - | - | 1 |
| Avg Price Target | - | - | $12.00 |
| Last Closing Price | $7.64 | $7.64 | $7.64 |
| Upside/Downside | -100.00% | -100.00% | 57.07% |
In the current month, the average price target of AngioDynamics stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to AngioDynamics's last price of $7.64. This month's average price target is down NaN% compared to last quarter, and down -100.00% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| Apr 05, 2024 | Oppenheimer | - | Outperform | Upgrade |
| Jan 09, 2024 | Raymond James | Outperform | Outperform | Hold |
| Jan 08, 2024 | Jefferies | Buy | Buy | Hold |
| Oct 06, 2023 | Raymond James | Outperform | Outperform | Hold |
| Jan 06, 2023 | Raymond James | Strong Buy | Strong Buy | Hold |
| Jul 13, 2022 | Raymond James | Strong Buy | Strong Buy | Hold |
AngioDynamics's last stock rating was published by Oppenheimer on Apr 05, 2024. The company Upgrade its ANGO rating from "null" to "Outperform".
AngioDynamics Financial Forecast
AngioDynamics Revenue Forecast
| May 25 | Mar 25 | Dec 24 | Aug 24 | May 24 | Mar 24 | Dec 23 | Aug 23 | May 23 | Mar 23 | Dec 22 | Aug 22 | May 22 | Mar 22 | Nov 21 | Aug 21 | May 21 | Mar 21 | Nov 20 | Aug 20 | May 20 | Feb 20 | Nov 19 | Aug 19 | May 19 | Mar 19 | Nov 18 | Aug 18 | May 18 | Mar 18 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | $78.68M | $91.07M | - | - | $81.54M | $87.00M | - | $78.28M | $76.97M | $76.84M | - | $72.77M | $70.22M | $58.33M | $69.78M | $70.00M | $66.04M | $7.45M | - | $91.50M | $85.34M | $88.32M | - |
| Avg Forecast | $74.60M | $70.90M | $70.93M | $67.93M | $70.86M | $74.21M | $81.16M | $77.70M | $90.73M | $83.19M | $84.38M | $78.44M | $83.25M | $76.32M | $77.91M | $71.30M | $72.67M | $68.95M | $67.35M | $65.11M | $62.86M | $68.55M | $71.27M | $67.74M | $92.33M | $88.30M | $87.34M | $96.01M | $92.73M | $63.73M |
| High Forecast | $74.60M | $70.90M | $70.93M | $68.44M | $70.86M | $74.21M | $82.20M | $77.70M | $90.73M | $83.19M | $84.38M | $94.13M | $99.90M | $82.01M | $83.72M | $76.62M | $78.09M | $74.09M | $72.37M | $69.96M | $67.55M | $73.66M | $76.58M | $72.79M | $99.22M | $94.88M | $104.81M | $115.21M | $111.28M | $76.47M |
| Low Forecast | $74.60M | $70.90M | $70.93M | $67.55M | $70.86M | $74.21M | $79.88M | $77.70M | $90.73M | $83.19M | $84.38M | $62.75M | $66.60M | $74.06M | $75.60M | $69.18M | $70.51M | $66.90M | $65.35M | $63.18M | $60.99M | $66.51M | $69.16M | $65.73M | $89.59M | $85.68M | $69.88M | $76.81M | $74.19M | $50.98M |
| # Analysts | 1 | - | 1 | 3 | 1 | 2 | 4 | 2 | 2 | 10 | 8 | 18 | 19 | 1 | 2 | 2 | 9 | 9 | 16 | 9 | 10 | 16 | 8 | 11 | 8 | 8 | 18 | 11 | 20 | 19 |
| Surprise % | - | - | - | - | - | - | - | 1.01% | 1.00% | - | - | 1.04% | 1.05% | - | 1.00% | 1.08% | 1.06% | - | 1.08% | 1.08% | 0.93% | 1.02% | 0.98% | 0.97% | 0.08% | - | 1.05% | 0.89% | 0.95% | - |
AngioDynamics's average Quarter revenue forecast for Dec 23 based on 4 analysts is $81.16M, with a low forecast of $79.88M, and a high forecast of $82.20M. ANGO's average Quarter revenue forecast represents a 3.15% increase compared to the company's last Quarter revenue of $78.68M (Aug 23).
AngioDynamics EBITDA Forecast
| May 25 | Mar 25 | Dec 24 | Aug 24 | May 24 | Mar 24 | Dec 23 | Aug 23 | May 23 | Mar 23 | Dec 22 | Aug 22 | May 22 | Mar 22 | Nov 21 | Aug 21 | May 21 | Mar 21 | Nov 20 | Aug 20 | May 20 | Feb 20 | Nov 19 | Aug 19 | May 19 | Mar 19 | Nov 18 | Aug 18 | May 18 | Mar 18 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | - | 1 | 3 | 1 | 2 | 4 | 2 | 2 | 10 | 8 | 18 | 19 | 1 | 2 | 2 | 9 | 9 | 16 | 9 | 10 | 16 | 8 | 11 | 8 | 8 | 18 | 11 | 20 | 19 |
| EBITDA | - | - | - | - | - | - | - | $35.03M | $5.00M | - | - | $-24.00K | $3.33M | - | $-1.41M | $-1.46M | $-15.23M | - | $1.50M | $1.98M | $-150.42M | $73.00K | $2.64M | $4.28M | $-9.90M | - | $10.75M | $6.04M | $9.93M | - |
| Avg Forecast | $1.81M | $1.72M | $1.72M | $1.65M | $1.72M | $13.12M | $1.97M | $1.89M | $2.20M | $10.37M | $2.05M | $-2.30M | $1.13M | $8.20M | $6.49M | $-2.10M | $6.05M | $6.69M | $3.37M | $4.07M | $-150.42M | $153.30K | $2.64M | $4.71M | $-10.28M | $10.67M | $10.24M | $6.71M | $10.41M | $7.20M |
| High Forecast | $1.81M | $1.72M | $1.72M | $1.66M | $1.72M | $15.74M | $2.00M | $1.89M | $2.20M | $12.45M | $2.05M | $-1.84M | $1.36M | $9.84M | $6.97M | $-1.68M | $6.50M | $8.03M | $4.04M | $4.89M | $-120.34M | $183.96K | $3.17M | $5.65M | $-8.23M | $12.80M | $12.29M | $8.05M | $12.49M | $8.64M |
| Low Forecast | $1.81M | $1.72M | $1.72M | $1.64M | $1.72M | $10.50M | $1.94M | $1.89M | $2.20M | $8.30M | $2.05M | $-2.77M | $904.80K | $6.56M | $6.29M | $-2.51M | $5.87M | $5.35M | $2.70M | $3.26M | $-180.50M | $122.64K | $2.11M | $3.77M | $-12.34M | $8.53M | $8.19M | $5.37M | $8.33M | $5.76M |
| Surprise % | - | - | - | - | - | - | - | 18.56% | 2.27% | - | - | 0.01% | 2.94% | - | -0.22% | 0.69% | -2.52% | - | 0.44% | 0.49% | 1.00% | 0.48% | 1.00% | 0.91% | 0.96% | - | 1.05% | 0.90% | 0.95% | - |
4 analysts predict ANGO's average Quarter EBITDA for Dec 23 to be $1.97M, with a high of $2.00M and a low of $1.94M. This is -94.37% lower than AngioDynamics's previous annual EBITDA (Aug 23) of $35.03M.
AngioDynamics Net Income Forecast
| May 25 | Mar 25 | Dec 24 | Aug 24 | May 24 | Mar 24 | Dec 23 | Aug 23 | May 23 | Mar 23 | Dec 22 | Aug 22 | May 22 | Mar 22 | Nov 21 | Aug 21 | May 21 | Mar 21 | Nov 20 | Aug 20 | May 20 | Feb 20 | Nov 19 | Aug 19 | May 19 | Mar 19 | Nov 18 | Aug 18 | May 18 | Mar 18 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | - | 1 | 3 | 1 | 2 | 4 | 2 | 2 | 10 | 8 | 18 | 19 | 1 | 2 | 2 | 9 | 9 | 16 | 9 | 10 | 16 | 8 | 11 | 8 | 8 | 18 | 11 | 20 | 19 |
| Net Income | - | - | - | - | - | - | - | $45.88M | $-21.47M | - | - | $-13.00M | $-6.27M | - | $-8.35M | $-6.97M | $-19.47M | - | $-4.27M | $-4.27M | $-157.07M | $-5.71M | $-2.74M | $-1.27M | $-13.61M | - | $2.14M | $-469.00K | $2.10M | - |
| Avg Forecast | $-2.43M | $-4.04M | $-4.18M | $-5.93M | $-6.74M | $-35.70M | $-2.98M | $-5.26M | $871.20K | $-28.22M | $-404.27K | $-11.04M | $-6.27M | $-22.31M | $76.10M | $-10.04M | $-134.10K | $-9.57M | $-9.60M | $-8.78M | $-157.07M | $-11.99M | $-2.74M | $-1.40M | $-14.14M | $904.54K | $2.04M | $-521.11K | $2.20M | $9.59M |
| High Forecast | $-2.43M | $-4.04M | $-4.18M | $-5.14M | $-6.74M | $-28.56M | $-1.99M | $-5.26M | $871.20K | $-22.58M | $-404.27K | $-8.83M | $-5.01M | $-17.85M | $83.48M | $-8.03M | $-128.92K | $-7.66M | $-7.68M | $-7.02M | $-125.65M | $-9.59M | $-2.19M | $-1.12M | $-11.31M | $1.09M | $2.45M | $-416.89K | $2.64M | $11.51M |
| Low Forecast | $-2.43M | $-4.04M | $-4.18M | $-6.32M | $-6.74M | $-42.84M | $-3.64M | $-5.26M | $871.20K | $-33.87M | $-404.27K | $-13.25M | $-7.52M | $-26.77M | $73.17M | $-12.05M | $-147.09K | $-11.48M | $-11.52M | $-10.54M | $-188.48M | $-14.39M | $-3.28M | $-1.68M | $-16.96M | $723.64K | $1.63M | $-625.33K | $1.76M | $7.67M |
| Surprise % | - | - | - | - | - | - | - | -8.73% | -24.64% | - | - | 1.18% | 1.00% | - | -0.11% | 0.69% | 145.18% | - | 0.44% | 0.49% | 1.00% | 0.48% | 1.00% | 0.91% | 0.96% | - | 1.05% | 0.90% | 0.95% | - |
AngioDynamics's average Quarter net income forecast for Dec 23 is $-2.98M, with a range of $-3.64M to $-1.99M. ANGO's average Quarter net income forecast represents a -106.49% decrease compared to the company's last Quarter net income of $45.88M (Aug 23).
AngioDynamics SG&A Forecast
| May 25 | Mar 25 | Dec 24 | Aug 24 | May 24 | Mar 24 | Dec 23 | Aug 23 | May 23 | Mar 23 | Dec 22 | Aug 22 | May 22 | Mar 22 | Nov 21 | Aug 21 | May 21 | Mar 21 | Nov 20 | Aug 20 | May 20 | Feb 20 | Nov 19 | Aug 19 | May 19 | Mar 19 | Nov 18 | Aug 18 | May 18 | Mar 18 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | - | 1 | 3 | 1 | 2 | 4 | 2 | 2 | 10 | 8 | 18 | 19 | 1 | 2 | 2 | 9 | 9 | 16 | 9 | 10 | 16 | 8 | 11 | 8 | 8 | 18 | 11 | 20 | 19 |
| SG&A | - | - | - | - | - | - | - | $38.22M | $36.52M | - | - | $36.64M | $37.94M | - | $33.28M | $33.39M | $32.95M | - | $29.39M | $26.26M | $26.43M | $31.14M | $31.11M | $27.83M | $26.00M | - | $29.61M | $27.93M | $28.84M | - |
| Avg Forecast | $32.27M | $30.67M | $30.68M | $29.39M | $30.65M | $32.10M | $35.11M | $33.61M | $39.25M | $35.99M | $36.50M | $52.89M | $37.94M | $30.77M | $31.41M | $48.08M | $29.30M | $27.80M | $66.13M | $54.02M | $26.43M | $65.39M | $31.11M | $30.62M | $27.00M | $32.04M | $28.20M | $31.03M | $30.22M | $17.61M |
| High Forecast | $32.27M | $30.67M | $30.68M | $29.61M | $30.65M | $32.10M | $35.56M | $33.61M | $39.25M | $35.99M | $36.50M | $63.47M | $45.52M | $33.06M | $33.75M | $57.70M | $31.48M | $29.87M | $79.36M | $64.83M | $31.71M | $78.47M | $37.33M | $36.74M | $32.40M | $38.44M | $33.83M | $37.24M | $36.26M | $21.13M |
| Low Forecast | $32.27M | $30.67M | $30.68M | $29.22M | $30.65M | $32.10M | $34.55M | $33.61M | $39.25M | $35.99M | $36.50M | $42.31M | $30.35M | $29.86M | $30.48M | $38.46M | $28.43M | $26.97M | $52.91M | $43.22M | $21.14M | $52.31M | $24.89M | $24.49M | $21.60M | $25.63M | $22.56M | $24.83M | $24.17M | $14.08M |
| Surprise % | - | - | - | - | - | - | - | 1.14% | 0.93% | - | - | 0.69% | 1.00% | - | 1.06% | 0.69% | 1.12% | - | 0.44% | 0.49% | 1.00% | 0.48% | 1.00% | 0.91% | 0.96% | - | 1.05% | 0.90% | 0.95% | - |
AngioDynamics's average Quarter SG&A projection for Dec 23 is $35.11M, based on 4 Wall Street analysts, with a range of $34.55M to $35.56M. The forecast indicates a -8.15% fall compared to ANGO last annual SG&A of $38.22M (Aug 23).
AngioDynamics EPS Forecast
| May 25 | Mar 25 | Dec 24 | Aug 24 | May 24 | Mar 24 | Dec 23 | Aug 23 | May 23 | Mar 23 | Dec 22 | Aug 22 | May 22 | Mar 22 | Nov 21 | Aug 21 | May 21 | Mar 21 | Nov 20 | Aug 20 | May 20 | Feb 20 | Nov 19 | Aug 19 | May 19 | Mar 19 | Nov 18 | Aug 18 | May 18 | Mar 18 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | - | 1 | 3 | 1 | 2 | 4 | 2 | 2 | 10 | 8 | 18 | 19 | 1 | 2 | 2 | 9 | 9 | 16 | 9 | 10 | 16 | 8 | 11 | 8 | 8 | 18 | 11 | 20 | 19 |
| EPS | - | - | - | - | - | - | - | $1.15 | $-0.54 | - | - | $-0.33 | $-0.16 | - | $-0.21 | $-0.18 | $-0.51 | - | $-0.11 | $-0.11 | $-4.10 | $-0.15 | $-0.07 | $-0.03 | $1.57 | - | $0.06 | $-0.01 | $0.06 | - |
| Avg Forecast | $-0.06 | $-0.10 | $-0.10 | $-0.15 | $-0.17 | $-0.15 | $-0.07 | $-0.13 | $0.02 | $-0.01 | $-0.01 | $1.27 | $1.15 | $-0.01 | $1.89 | $-0.04 | $-0.00 | $-0.02 | $-0.02 | $-0.07 | $-0.06 | $-0.03 | $0.02 | $0.04 | $0.26 | $0.21 | $0.20 | $0.20 | $0.22 | $0.13 |
| High Forecast | $-0.06 | $-0.10 | $-0.10 | $-0.13 | $-0.17 | $-0.15 | $-0.05 | $-0.13 | $0.02 | $-0.01 | $-0.01 | $1.27 | $1.15 | $-0.01 | $2.07 | $-0.04 | $-0.00 | $-0.02 | $-0.02 | $-0.06 | $-0.05 | $-0.03 | $0.03 | $0.05 | $0.28 | $0.24 | $0.24 | $0.24 | $0.26 | $0.16 |
| Low Forecast | $-0.06 | $-0.10 | $-0.10 | $-0.16 | $-0.17 | $-0.15 | $-0.09 | $-0.13 | $0.02 | $-0.01 | $-0.01 | $1.27 | $1.15 | $-0.01 | $1.82 | $-0.05 | $-0.00 | $-0.03 | $-0.02 | $-0.07 | $-0.06 | $-0.03 | $0.02 | $0.04 | $0.25 | $0.21 | $0.16 | $0.16 | $0.18 | $0.10 |
| Surprise % | - | - | - | - | - | - | - | -8.85% | -25.06% | - | - | -0.26% | -0.14% | - | -0.11% | 4.00% | 153.02% | - | 5.50% | 1.65% | 72.35% | 5.00% | -3.00% | -0.71% | 6.16% | - | 0.30% | -0.05% | 0.27% | - |
According to 4 Wall Street analysts, AngioDynamics's projected average Quarter EPS for Dec 23 is $-0.07, with a low estimate of $-0.09 and a high estimate of $-0.05. This represents a -106.41% decrease compared to ANGO previous annual EPS of $1.15 (Aug 23).
AngioDynamics Peer Comparison by Price Target
| Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
|---|---|---|---|---|---|
| NSTG | NanoString | $0.11 | $21.50 | 19445.45% | Buy |
| COO | Cooper Companies | $110.53 | $298.00 | 169.61% | Buy |
| AKYA | Akoya Biosciences | $2.94 | $7.90 | 168.71% | Buy |
| ANGO | AngioDynamics | $7.64 | $17.00 | 122.51% | Buy |
| ATRC | AtriCure | $28.21 | $49.57 | 75.72% | Buy |
| KRMD | KORU Medical Systems | $2.50 | $3.75 | 50.00% | Buy |
| HAE | Haemonetics | $76.09 | $104.33 | 37.11% | Buy |
| NVST | Envista | $19.41 | $23.83 | 22.77% | Hold |
| MMSI | Merit Medical Systems | $96.16 | $93.38 | -2.89% | Buy |
| ICUI | ICU Medical | $179.00 | $135.00 | -24.58% | Buy |
| ATR | AptarGroup | $152.28 | $100.00 | -34.33% | Buy |
ANGO Forecast FAQ
Is AngioDynamics a good buy?
Yes, according to 3 Wall Street analysts, AngioDynamics (ANGO) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 3 'Buy' recommendations, accounting for 100.00% of ANGO's total ratings.
What is ANGO's price target?
AngioDynamics (ANGO) average price target is $17 with a range of $12 to $22, implying a 122.51% from its last price of $7.64. The data is based on 3 Wall Street analysts who provided a twelve-month price target estimate in the last three months.
Will AngioDynamics stock go up soon?
According to Wall Street analysts' prediction for ANGO stock, the company can go up by 122.51% (from the last price of $7.64 to the average price target of $17), up by 187.96% based on the highest stock price target, and up by 57.07% based on the lowest stock price target.
Can AngioDynamics stock reach $11?
ANGO's average twelve months analyst stock price target of $17 supports the claim that AngioDynamics can reach $11 in the near future.
What are AngioDynamics's analysts' financial forecasts?
AngioDynamics's analysts financial forecasts for the fiscal year (May 2024) are as follows: average revenue is $303.92M (high $304.96M, low $302.64M), average EBITDA is $18.7M (high $21.35M, low $16.04M), average net income is $-50.676M (high $-42.542M, low $-58.478M), average SG&A $131.47M (high $131.92M, low $130.92M), and average EPS is $-0.525 (high $-0.501, low $-0.542). ANGO's analysts financial forecasts for the fiscal year (May 2025) are as follows: average revenue is $284.37M (high $284.87M, low $283.98M), average EBITDA is $6.91M (high $6.92M, low $6.9M), average net income is $-16.575M (high $-15.784M, low $-16.97M), average SG&A $123.01M (high $123.23M, low $122.84M), and average EPS is $-0.41 (high $-0.39, low $-0.42).
Did the ANGO's actual financial results beat the analysts' financial forecasts?
Based on AngioDynamics's last annual report (May 2023), the company's revenue was $338.75M, beating the average analysts forecast of $336.75M by 0.59%. Apple's EBITDA was $11.64M, missing the average prediction of $12.32M by -5.52%. The company's net income was $-52.442M, beating the average estimation of $-38.8M by 35.16%. Apple's SG&A was $144.25M, missing the average forecast of $164.63M by -12.38%. Lastly, the company's EPS was $-1.33, missing the average prediction of $1.28 by -204.26%. In terms of the last quarterly report (Aug 2023), AngioDynamics's revenue was $78.68M, beating the average analysts' forecast of $77.7M by 1.26%. The company's EBITDA was $35.03M, beating the average prediction of $1.89M by 1756.03%. AngioDynamics's net income was $45.88M, missing the average estimation of $-5.256M by -973.06%. The company's SG&A was $38.22M, beating the average forecast of $33.61M by 13.72%. Lastly, the company's EPS was $1.15, missing the average prediction of $-0.13 by -984.62%